NO20041485L - Farmasoytisk formulering omfattende (R)-bicalutamid - Google Patents

Farmasoytisk formulering omfattende (R)-bicalutamid

Info

Publication number
NO20041485L
NO20041485L NO20041485A NO20041485A NO20041485L NO 20041485 L NO20041485 L NO 20041485L NO 20041485 A NO20041485 A NO 20041485A NO 20041485 A NO20041485 A NO 20041485A NO 20041485 L NO20041485 L NO 20041485L
Authority
NO
Norway
Prior art keywords
bicalutamide
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
NO20041485A
Other languages
English (en)
Inventor
Nicola Frances Bateman
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20041485L publication Critical patent/NO20041485L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20041485A 2001-10-15 2004-04-13 Farmasoytisk formulering omfattende (R)-bicalutamid NO20041485L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation
PCT/GB2002/004621 WO2003032950A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide

Publications (1)

Publication Number Publication Date
NO20041485L true NO20041485L (no) 2004-04-13

Family

ID=20285650

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041485A NO20041485L (no) 2001-10-15 2004-04-13 Farmasoytisk formulering omfattende (R)-bicalutamid

Country Status (19)

Country Link
US (1) US20060058381A1 (no)
EP (1) EP1439823A1 (no)
JP (1) JP3639587B2 (no)
KR (1) KR20050035163A (no)
CN (1) CN1571658A (no)
AR (1) AR036877A1 (no)
BR (1) BR0213248A (no)
CA (1) CA2462219A1 (no)
CO (1) CO5580755A2 (no)
HU (1) HUP0401369A3 (no)
IL (1) IL161306A0 (no)
IS (1) IS7219A (no)
MX (1) MXPA04003520A (no)
NO (1) NO20041485L (no)
PL (1) PL368226A1 (no)
RU (1) RU2004115023A (no)
SE (1) SE0103424D0 (no)
WO (1) WO2003032950A1 (no)
ZA (1) ZA200402729B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032225A3 (cs) * 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
RU2766487C2 (ru) 2004-01-20 2022-03-15 Новартис Аг Композиция и способ прямого прессования
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
CN103813794A (zh) * 2011-07-18 2014-05-21 拓凯制药公司 用于治疗前列腺癌的新型组合物及方法
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
HUE054935T2 (hu) 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
SG11201704267VA (en) * 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629237A (en) * 1968-09-12 1971-12-21 Shinetsu Chemical Co Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
AU1687395A (en) * 1994-01-21 1995-08-08 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
CZ20032225A3 (cs) * 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
EP1381358B1 (en) * 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp

Also Published As

Publication number Publication date
ZA200402729B (en) 2005-01-13
WO2003032950A1 (en) 2003-04-24
PL368226A1 (en) 2005-03-21
US20060058381A1 (en) 2006-03-16
HUP0401369A2 (hu) 2004-11-29
CA2462219A1 (en) 2003-04-24
CN1571658A (zh) 2005-01-26
RU2004115023A (ru) 2005-04-10
JP2004521963A (ja) 2004-07-22
CO5580755A2 (es) 2005-11-30
KR20050035163A (ko) 2005-04-15
IS7219A (is) 2004-04-14
BR0213248A (pt) 2004-09-28
AR036877A1 (es) 2004-10-13
JP3639587B2 (ja) 2005-04-20
IL161306A0 (en) 2004-09-27
EP1439823A1 (en) 2004-07-28
SE0103424D0 (sv) 2001-10-15
MXPA04003520A (es) 2004-07-23
HUP0401369A3 (en) 2006-05-29

Similar Documents

Publication Publication Date Title
NO20033384L (no) Farmasoytisk formulering
NO20033785D0 (no) Farmasöytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
ITTO20010008A0 (it) Formulazione farmaceutica
FI20011478L (fi) Farmaseuttinen koostumus
NO20035627D0 (no) Farmasöytisk formulering
EE200300589A (et) Ravimkoostised
FI20022128A7 (fi) Farmaseuttinen koostumus
EP1408896A4 (en) PHARMACEUTICAL COMPOSITION
NO20042502L (no) Farmasoytisk formulering omfattende bicalutamid
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DK1429753T3 (da) Farmaceutisk sammensætning omfattende gamma-butyrobetain
NO20015534D0 (no) Farmasöytisk blandeapparat
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE10107261B4 (de) Pharmazeutische Zusammensetzung
NO20041236L (no) Farmasoytisk formulering
SE0101171D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation
EP1413314A4 (en) MEDICAL COMPOSITIONS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application